Year 2025 / Volume 117 / Number 2
Letter
Inflammatory bowel disease secondary to treatment with ixekizumab in a patient with difficult-to-manage psoriasis

113-114

DOI: 10.17235/reed.2024.10290/2024

Eugenia Navarro Moreno, Marta Lázaro Sáez, José Luis Vega Sáenz,

Abstract
Both psoriasis and inflammatory bowel disease (IBD) are immunomediated diseases. Some of their therapeutic tools are monoclonal antibodies. Ixekizumab is an interleukin-17 (IL-17) inhibitor approved for the treatment of psoriasis. Cases of IBD onset have been reported in patients treated with this drug. We present the case of a 35-year-old patient with the onset of ulcerative colitis (UC) type of IBD after starting ixekizumab treatment.
New comment
Comments
No comments for this article
Citation tools
Navarro Moreno E, Lázaro Sáez M, Vega Sáenz J. Inflammatory bowel disease secondary to treatment with ixekizumab in a patient with difficult-to-manage psoriasis. 10290/2024


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 213 visits.
This article has been downloaded 30 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 21/01/2024

Accepted: 06/02/2024

Online First: 12/02/2024

Published: 05/02/2025

Article Online First time: 22 days

Article editing time: 381 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2025 y Creative Commons. The Spanish Journal of Gastroenterology